Interleukin 18

David Schoenfeld, MD, PhD, Yale School of Medicine, New Haven, CT, provides an overview of the decoy-resistant IL-

Explore the intriguing world of IL-

Ed Behrens giving a talk regarding Targeting IL

This is an introductory video about IL-18 (aka

0:05 Grant Schulert, MD, PhD - Introducing Masaki Shimizu 1:47 Masaki Shimizu, MD, PhD - Clinical significance of serum IL-

Eran Ophir, PhD, Compugen Ltd.,Tel Aviv, Israel, discusses COM503, a potential first-in-class, high affinity anti- IL18 binding ...

Long COVID in Autoimmune Patients: Could Low IL-

Dr. Scott Canna provides an overview of autoinflammatory biomarkers, with a focus on Still's disease and cytokine storm.

Controlling the inflammation caused by IL-18. What the IL-18/IL-18BP tells us.

Interleukin

Understanding the Pathway article: http://ascopubs.org/doi/full/10.1200/JCO.2016.69.6435 The Journal of Clinical Oncology's ...

And so so do you think that's a better minimal residual disease activity marker then

Speaker: Dr. Charles Dinarello, 2020 Tang Prize Laureate in Biopharmaceutical Science.

During this webinar, the first one in our ECR focused webinar series, we provided the opportunity for Jack and Cian – both early ...

Jakub Svoboda, MD, associate professor, medicine, Hematology-Oncology, attending, the Hospital of the University of ...

... the innate immune response these include il-1 alpha beta and il-

Walter and Eliza Hall Institute Wednesday Seminar 11 November 2015 Dr Seth Masters Inflammation division.

Dr. Scott Canna discussing Targetting IL18 at the Next Gen Therapies for SJIA & MAS Conference. Conference Playlist: ...

Contents: Panel moderated by Dan Lovell: 0:00 - Fabrizio De Benedetti & Scott Canna : It is time for IL-

Panel Discussion of IL18 and Interferon Gamma during the Next Gen therapies in SJIA & MAS conference. Conference Playlist: ...